Patents Assigned to NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
  • Publication number: 20220162604
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Application
    Filed: June 30, 2021
    Publication date: May 26, 2022
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Publication number: 20220127606
    Abstract: Provided are a complex that comprises a nucleic acid-containing nanoparticle and a hollow particle of a non-enveloped virus, a method for producing the complex, and a pharmaceutical composition comprising the complex.
    Type: Application
    Filed: January 29, 2020
    Publication date: April 28, 2022
    Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON MEDICAL SCHOOL FOUNDATION
    Inventors: Takashi Okada, Hiromi KINOH, Yoshitsugu AOKI, Shin'ichi TAKEDA
  • Publication number: 20220047521
    Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at ?5 to 50° C. to introduce the drug into the empty capsid or the empty particle.
    Type: Application
    Filed: November 2, 2021
    Publication date: February 17, 2022
    Applicant: National Center of Neurology and Psychiatry
    Inventors: Takashi Okada, Shin'ichi Takeda, Hiromi Kinoh
  • Publication number: 20220049257
    Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.
    Type: Application
    Filed: November 2, 2021
    Publication date: February 17, 2022
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Yuuichirou TONE, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Patent number: 11191733
    Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at ?5 to 50° C. to introduce the drug into the empty capsid or the empty particle.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: December 7, 2021
    Assignee: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Takashi Okada, Shin'ichi Takeda, Hiromi Kinoh
  • Patent number: 11193125
    Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: December 7, 2021
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Yuuichirou Tone, Shin'ichi Takeda, Tetsuya Nagata
  • Patent number: 11174317
    Abstract: The present invention provides a novel therapeutic agent for mental illness. The therapeutic agent for mental illness comprises an IL-6 inhibitor as an active ingredient.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 16, 2021
    Assignees: National Center of Neurology and Psychiatry, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroshi Kunugi, Chisato Wakabayashi
  • Publication number: 20210340171
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: July 14, 2021
    Publication date: November 4, 2021
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Publication number: 20210284680
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: May 28, 2021
    Publication date: September 16, 2021
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Publication number: 20210246173
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 12, 2021
    Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi OKADA, Hironori OKADA, Hiromi KINOH, Tatsuji ENOKI, Toshikazu NISHIE, Junichi MINENO
  • Publication number: 20210222169
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Application
    Filed: August 21, 2020
    Publication date: July 22, 2021
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Haruna SEO, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Patent number: 11062175
    Abstract: A reduced attention state estimation system includes an eyeball movement and eyelid activity measurement unit that measures an eyeball movement and an eyelid activity of a subject to obtain eyeball movement and eyelid activity data, a section determination unit that determines an eye opening section, an eye closing section, an eye-blinking section and a cluster section based on the eyeball movement and eyelid activity data, an eyeball movement and eyelid activity-related information calculation unit that calculates a sharpness of microsaccade or the like for each eye opening section based on the eyeball movement and eyelid activity data, and an attention assessment unit that determines an attention assessment or the like for an eye opening/cluster section, which is an eye opening section and cluster section, based on the sharpness of microsaccade or the like.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 13, 2021
    Assignees: Japan Aerospace Exploration Agency, National Center of Neurology and Psychiatry
    Inventors: Takashi Abe, Satoshi Furukawa, Katsuhiko Ogata, Kazuo Mishima, Shingo Kitamura
  • Patent number: 11053497
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: July 6, 2021
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Publication number: 20210198306
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: February 12, 2021
    Publication date: July 1, 2021
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Publication number: 20210179659
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 17, 2021
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Patent number: 11028122
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: June 8, 2021
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Patent number: 11028131
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 8, 2021
    Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi Okada, Hironori Okada, Hiromi Kinoh, Tatsuji Enoki, Toshikazu Nishie, Junichi Mineno
  • Publication number: 20210147839
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Application
    Filed: November 17, 2020
    Publication date: May 20, 2021
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • Publication number: 20210087560
    Abstract: An object of the present invention is to provide a vector capable of oligodendrocyte-specifically suppressing expression of the PLP1 gene for treating PMD caused by abnormality of the PLP1 gene, and a promoter and miRNA therefor, and a pharmaceutical composition comprising the vector. The oligodendrocyte-specific promoter of the present invention comprises a nucleic acid having a sequence identity of at least 90% to a nucleotide sequence set forth in SEQ ID NO: 1. The miRNA of the present invention specific to the PLP1 gene comprises a pair of nucleotide sequences consisting of a specific antisense sequence and sense sequence.
    Type: Application
    Filed: February 6, 2019
    Publication date: March 25, 2021
    Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON MEDICAL SCHOOL FOUNDATION, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ken Inoue, Heng Li, Takashi Okada, Yu Ohki, Makoto Koizumi
  • Patent number: 10934543
    Abstract: Provided is an agent developed to be capable of alleviating and suppressing muscle atrophy or muscle mass decrease, even for the elderly and even without requiring exercise, by inducing muscle differentiation. Provided is a composition for treating or preventing disorders or diseases associated with muscle atrophy, or for promoting muscle regeneration, the composition comprising, as an active ingredient, an inducer of muscle differentiation consisting of miR-199 or DNA that contains miR-199 gene encoding the miR-199.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 2, 2021
    Assignee: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Hirohiko Hohjoh, Masashi Fukuoka